Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update
Trinity Biotech announced continued execution of its transformation strategy, including commercial leadership strengthening in Europe, rollout of upgraded HbA1c column technology, and expansion of its PrePsia™ patent portfolio to nine patents. However, the company received a Nasdaq delisting notice after failing to maintain the $15 million minimum market value of publicly held shares requirement by the August 18, 2026 deadline. The company intends to request a hearing before a Nasdaq panel and is pursuing strategic initiatives to regain compliance.